EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

DGAT1 and DGAT2 Inhibitors for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Management: Benefits for Their Single or Combined Application

Miriam Longo, Erika Paolini, Pietro Di Benedetto, Elena Tomassini, Marica Meroni iD, Paola Dongiovanni iD

International Journal of Molecular Sciences · 21.08.2024 · 25 (16) · 9074

DOI: 10.3390/ijms25169074 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 21.08.2024. Verfasst von Miriam Longo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Medicine and Metabolic Diseases, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy. Hauptthemen laut MEDLINE: Diacylglycerol O-Acyltransferase, Triglycerides. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Minister of Health, Italian Ministry of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inhibiting diacylglycerol acetyltransferase (DGAT1, DGAT2) enzymes (iDGAT1, iDGAT2), involved in triglyceride (TG) synthesis, improves hepatic steatosis in metabolic dysfunction-associated steatotic liver disease (MASLD) patients. However, their potential synergism in disease onset (SLD) and progression (metabolic dysfunction-associated steatohepatitis, fibrosis) has been poorly explored. We investigated iDGAT1 and iDGAT2 efficacy, alone or combined (iDGAT1/2) on fat accumulation and hepatocellular injury in hepatocytes (HepG2) and on fibrogenic processes in hepatic stellate cells (LX2). We further tested whether the addition of MitoQ antioxidant to iDGAT1/2 would enhance their effects. SLD and MASH conditions were reproduced in vitro by supplementing Dulbecco’s Modified Eagle’s Medium (DMEM) with palmitic/oleic acids (PAOA) alone (SLD-medium), or plus Lipopolisaccaride (LPS), fructose, and glucose (MASH-medium). In SLD-medium, iDGAT1 and iDGAT2 individually, and even more in combination, reduced TG synthesis in HepG2 cells. Markers of hepatocellular damage were slightly decreased after single iDGAT exposure. Conversely, iDGAT1/2 counteracted ER/oxidative stress and inflammation and enhanced mitochondrial Tricarboxylic acid cycle (TCA) and respiration. In HepG2 cells under a MASH-like condition, only iDGAT1/2 effectively ameliorated TG content and oxidative and inflammatory mediators, further improving bioenergetic balance. LX2 cells, challenged with SLD/MASH media, showed less proliferation and slower migration rates in response to iDGAT1/2 drugs. MitoQ combined with iDGAT1/2 improved cell viability and dampened free fatty acid release by stimulating β-oxidation. Dual DGAT inhibition combined with antioxidants open new perspectives for MASLD management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diacylglycerol O-AcyltransferaseTriglyceridesHumansHep G2 CellsEnzyme InhibitorsHepatic Stellate CellsFatty LiverOxidative StressAntioxidantsHepatocytes

Stichwörter der Autor:innen

DGATMASHMASLDfibrosispharmacological therapy

Substanzen

Diacylglycerol O-AcyltransferaseDGAT2 protein, humanDGAT1 protein, humanTriglyceridesEnzyme InhibitorsAntioxidants

Autor:innen und Institutionen

  • Medicine and Metabolic Diseases, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.

ORCID-Profile: Marica Meroni, Paola Dongiovanni

Förderung

  • Minister of Health
  • Italian Ministry of Health

Zitieren

APA

Longo, M., Paolini, E., Di Benedetto, P., Tomassini, E., Meroni, M., & Dongiovanni, P. (2024). DGAT1 and DGAT2 Inhibitors for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Management: Benefits for Their Single or Combined Application. International Journal of Molecular Sciences, 25(16), 9074. https://doi.org/10.3390/ijms25169074

Vancouver

Longo M, Paolini E, Di Benedetto P, Tomassini E, Meroni M, Dongiovanni P. DGAT1 and DGAT2 Inhibitors for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Management: Benefits for Their Single or Combined Application. International Journal of Molecular Sciences. 2024;25(16):9074. doi:10.3390/ijms25169074

BibTeX
@article{Longo2024,
  author = {Longo, Miriam and Paolini, Erika and Di Benedetto, Pietro and Tomassini, Elena and Meroni, Marica and Dongiovanni, Paola},
  title = {DGAT1 and DGAT2 Inhibitors for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Management: Benefits for Their Single or Combined Application},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {16},
  pages = {9074},
  doi = {10.3390/ijms25169074}
}
Kostenlos starten →